搜索
Charles River Laboratories International Inc
CRL173.720USD
-1.180-0.67%
收盘 04/02, 16:00（美东）报价延迟15分钟
8.51B总市值
亏损市盈率 TTM
关于 Charles River Laboratories International Inc 公司
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Charles River Laboratories International Inc简介
公司代码CRL
公司名称Charles River Laboratories International Inc
上市日期Jun 23, 2000
CEOFoster (James C)
员工数量18600
证券类型Ordinary Share
年结日Jun 23
公司地址251 Ballardvale St
城市WILMINGTON
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编01887
电话17812226000
网址https://www.criver.com/
公司代码CRL
上市日期Jun 23, 2000
CEOFoster (James C)
Charles River Laboratories International Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
309.13K
+5.43%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
64.16K
+10.04%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
21.60K
+17.18%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
16.05K
+19.74%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
15.81K
+0.16%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+19.26%
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
3.96K
+23.86%
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Independent Director
2.59K
+60.85%
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Independent Director
2.41K
+39.20%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
946.00
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
309.13K
+5.43%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
64.16K
+10.04%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
21.60K
+17.18%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
16.05K
+19.74%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
15.81K
+0.16%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+19.26%
收入明细
单位: USD更新时间: 2 小时前
单位: USD更新时间: 2 小时前
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
业务USD
名称
营收
占比
DSA
2.40B
59.84%
RMS
846.08M
21.07%
Manufacturing
766.41M
19.09%
地区USD
名称
营收
占比
United States
2.14B
53.34%
Europe
1.10B
27.46%
Canada
501.02M
12.48%
Asia Pacific (Region)
205.02M
5.11%
Other
64.86M
1.62%
业务
地区
业务USD
名称
营收
占比
DSA
2.40B
59.84%
RMS
846.08M
21.07%
Manufacturing
766.41M
19.09%
股东统计
更新时间: 3月28日 周六
更新时间: 3月28日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.93%
BlackRock Institutional Trust Company, N.A.
5.85%
Allspring Global Investments, LLC
4.05%
State Street Investment Management (US)
3.80%
Invesco Advisers, Inc.
3.61%
其他
70.76%
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.93%
BlackRock Institutional Trust Company, N.A.
5.85%
Allspring Global Investments, LLC
4.05%
State Street Investment Management (US)
3.80%
Invesco Advisers, Inc.
3.61%
其他
70.76%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
48.67%
Investment Advisor
47.43%
Hedge Fund
9.25%
Research Firm
2.28%
Pension Fund
1.46%
Individual Investor
1.13%
Sovereign Wealth Fund
0.99%
Bank and Trust
0.71%
Family Office
0.09%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
1367
52.25M
129.09%
+28.56K
2025Q3
1413
52.22M
129.54%
+64.86K
2025Q2
1411
52.12M
127.74%
-2.86M
2025Q1
1414
54.69M
123.53%
-5.98M
2024Q4
1410
54.25M
114.75%
+1.17M
2024Q3
1372
53.38M
114.53%
-33.66K
2024Q2
1378
53.46M
111.45%
+347.48K
2024Q1
1371
53.18M
111.09%
-4.05M
2023Q4
1405
52.96M
112.24%
-202.82K
2023Q3
1421
52.99M
111.08%
+631.82K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
5.88M
11.93%
+47.43K
+0.81%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
2.88M
5.85%
+56.48K
+2.00%
Dec 31, 2025
Allspring Global Investments, LLC
2.00M
4.05%
-182.34K
-8.37%
Dec 31, 2025
State Street Investment Management (US)
1.87M
3.8%
+40.53K
+2.21%
Dec 31, 2025
Invesco Advisers, Inc.
1.78M
3.61%
+1.63M
+1113.97%
Dec 31, 2025
Wellington Management Company, LLP
1.75M
3.55%
-1.44M
-45.17%
Dec 31, 2025
Harris Associates L.P.
1.68M
3.41%
+204.52K
+13.88%
Dec 31, 2025
Fidelity Management & Research Company LLC
1.55M
3.15%
+1.15M
+293.11%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
1.44M
2.93%
+311.32K
+27.53%
Dec 31, 2025
Ariel Investments, LLC
1.43M
2.9%
-62.33K
-4.18%
Dec 31, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco S&P 500 Equal Weight Health Care ETF
1.92%
Schwab Ariel Opportunities ETF
1.82%
iShares Health Innovation Active ETF
1.74%
First Trust NASDAQ Pharmaceuticals ETF
1.71%
ROBO Global Healthcare Technology & Innovation ETF
1.69%
VanEck Biotech ETF
1.44%
Franklin Genomic Advancements ETF
1.42%
WisdomTree US Value Fund
1.15%
Invesco S&P 500 High Beta ETF
1.14%
Pacer Lunt Large Cap Alternator ETF
0.97%
查看更多
Invesco S&P 500 Equal Weight Health Care ETF
占比1.92%
Schwab Ariel Opportunities ETF
占比1.82%
iShares Health Innovation Active ETF
占比1.74%
First Trust NASDAQ Pharmaceuticals ETF
占比1.71%
ROBO Global Healthcare Technology & Innovation ETF
占比1.69%
VanEck Biotech ETF
占比1.44%
Franklin Genomic Advancements ETF
占比1.42%
WisdomTree US Value Fund
占比1.15%
Invesco S&P 500 High Beta ETF
占比1.14%
Pacer Lunt Large Cap Alternator ETF
占比0.97%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
